Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | LYPLA1 | O75608 | 1/20 | 0.38 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225910 | 0.92 | EPHX2 (0.58) | EPHX2CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL12606929 | 0.89 | EPHX2 (0.55) | EPHX2CYP2D6KCNH2HRH3EPHX1 | |
| SCHEMBL12384517 | 0.87 | EPHX2 (0.53) | EPHX2CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL1104706 | 0.87 | EPHX2 (0.53) | EPHX2CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL25018493 | 0.87 | EPHX2 (0.57) | EPHX2CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL10292648 | 0.84 | EPHX2 (0.50) | EPHX2CYP2D6KCNH2HRH3CYP1A2 | |
| SCHEMBL17281941 | 0.84 | EPHX2 (0.51) | EPHX2CYP2D6KCNH2HRH3HSD11B1 | |
| SCHEMBL17471118 | 0.84 | EPHX2 (0.72) | EPHX2CYP2D6KCNH2HRH3EPHX1 | |
| SCHEMBL12384667 | 0.83 | EPHX2 (0.77) | EPHX2CYP2D6KCNH2HRH3EPHX1 | |
| SCHEMBL26783941 | 0.83 | EPHX2 (0.49) | EPHX2CYP2D6KCNH2HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 348 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | ARTUS THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | FULCRUM THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | GENENTECH, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-7291612-B2 | Immunomodulatory compounds | ACTIVE BIOTECH A.B. (SE) | 2007-11-06 | — | — | US | disclosed |
| US-7291612-B2 | Immunomodulatory compounds | ACTIVE BIOTECH A.B. (SE) | 2007-11-06 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-7160877-B2 | Aliphatic nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058327-A1 | 4-piperazinyl-5H-6,7-dihydrocyclopenta(d)pyrimidines; Hyperproliferative diseases such as cancer | PIK3CA, DPYD, CDK2 | EPHX2 2196/4885CYP2D6 381/4885KCNH2 4528/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | EPHX2 3405/4885CYP2D6 1586/4885KCNH2 3026/4885 |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | EPHX2 1845/4885CYP2D6 2792/4885KCNH2 4416/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | EPHX2 1000/4885CYP2D6 2650/4885KCNH2 3568/4885 |
| US-20240238296-A1 | METHODS OF REGULATING BCL11A EXPRESSION AND TREATMENT OF BCL11A-MEDIATED DISORDERS | BCLAF1, EED, BCL3 | EPHX2 597/4885CYP2D6 4334/4885KCNH2 4525/4885 |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | EPHX2 2203/4885CYP2D6 860/4885KCNH2 4688/4885 |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | EPHX2 3958/4885CYP2D6 2611/4885KCNH2 4395/4885 |
| US-20240239809-A1 | THERAPEUTIC AGENTS FOR ENHANCING EPITHELIAL AND/OR ENDOTHELIAL BARRIER FUNCTION | LIPG, FABP2, EPCAM | EPHX2 736/4885CYP2D6 4869/4885KCNH2 4019/4885 |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | EPHX2 1107/4885CYP2D6 2413/4885KCNH2 4333/4885 |
| US-20080033002-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | EPHX2 1111/4885CYP2D6 1646/4885KCNH2 571/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | EPHX2 1798/4885CYP2D6 3058/4885KCNH2 3469/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | EPHX2 1253/4885CYP2D6 33/4885KCNH2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.